遗传性发育性及癫痫性脑病患者的癫痫持续状态与癫痫猝死发生率
该回顾性分析纳入510例遗传性发育性及癫痫性脑病患者,评估惊厥性及非惊厥性癫痫持续状态与癫痫猝死的比例。结果显示惊厥性癫痫持续状态占47%、非惊厥性占19%,死亡42/510(8%),其中癫痫猝死占19/42(48%),估算癫痫猝死发生率为2.8/1000人年(95%CI 1.6-4.3)。
要点
- SCN1A相关DEE中惊厥性癫痫持续状态比例最高,Dravet综合征为181/203(89%)。
- 非惊厥性癫痫持续状态在非Dravet SCN1A-DEE中为8/15(53%),CHD2-DEE为6/14(43%)。
- 队列死亡42/510(8%),癫痫猝死占19/42(48%),涉及SCN1A、SCN2A、SCN8A和STXBP1。
核心结论
- 常见遗传性DEE患者的惊厥性癫痫持续状态、非惊厥性癫痫持续状态和癫痫猝死比例因基因诊断而异。
- 各遗传性DEE的估计值有助于癫痫持续状态和癫痫猝死的早期诊断与管理,并有助于针对患者和家庭进行疾病特异性咨询。
研究设计与样本
- 回顾性分析,纳入510例携带SCN1A、SCN2A、SCN8A、SYNGAP1、NEXMIF、CHD2、PCDH19、STXBP1、GRIN2A、KCNT1或KCNQ2致病变异或Angelman综合征(AS)的遗传性DEE患者。
- 按基因诊断估计惊厥性癫痫持续状态、非惊厥性癫痫持续状态和癫痫猝死的比例,以及总体死亡率和癫痫猝死特异性死亡率。
主要发现
- 队列中惊厥性癫痫持续状态占47%,非惊厥性癫痫持续状态占19%。
- 惊厥性癫痫持续状态比例最高见于SCN1A相关DEE:Dravet综合征181/203(89%;95%CI 84-93),非Dravet SCN1A-DEE 8/15(53%;95%CI 27-79)。
- 惊厥性癫痫持续状态还见于KCNT1(6/10;60%;95%CI 26-88)和SCN2A(8/15;53%;95%CI 27-79)。
- 非惊厥性癫痫持续状态常见于非Dravet SCN1A-DEE(8/15;53%;95%CI 27-79),并见于CHD2-DEE(6/14;43%;95%CI 18-71)和AS(6/19;32%;95%CI 13-57)。
- 死亡42/510(8%),死亡率6.1/1000人年(95%CI 4.4-8.3);癫痫猝死占19/42(48%),涉及SCN1A、SCN2A、SCN8A和STXBP1,估算癫痫猝死发生率2.8/1000人年(95%CI 1.6-4.3)。
关键数值与推荐
- Dravet综合征惊厥性癫痫持续状态181/203(89%;95%CI 84-93)。
- 非Dravet SCN1A-DEE惊厥性癫痫持续状态8/15(53%;95%CI 27-79),非惊厥性癫痫持续状态8/15(53%;95%CI 27-79)。
- KCNT1惊厥性癫痫持续状态6/10(60%;95%CI 26-88);SCN2A惊厥性癫痫持续状态8/15(53%;95%CI 27-79)。
- CHD2-DEE非惊厥性癫痫持续状态6/14(43%;95%CI 18-71);AS非惊厥性癫痫持续状态6/19(32%;95%CI 13-57)。
- 队列死亡率6.1/1000人年(95%CI 4.4-8.3);癫痫猝死发生率2.8/1000人年(95%CI 1.6-4.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The genetic developmental and epileptic encephalopathies (DEEs) comprise a large group of severe epilepsy syndromes, with a wide phenotypic spectrum. Currently, the rates of convulsive status epilepticus (CSE), nonconvulsive status epilepticus (NCSE), and sudden unexplained death in epilepsy (SUDEP) in these diseases are not well understood. We aimed to describe the proportions of patients with frequently observed genetic DEEs who developed CSE, NCSE, mortality, and SUDEP. Understanding the risks of these serious presentations in each genetic DEE will enable earlier diagnosis and appropriate management. METHODS: In this retrospective analysis of patients with a genetic DEE, we estimated the proportions with CSE, NCSE, and SUDEP and the overall and SUDEP-specific mortality rates for each genetic diagnosis. We included patients with a pathogenic variant in the genes SCN1A, SCN2A, SCN8A, SYNGAP1, NEXMIF, CHD2, PCDH19, STXBP1, GRIN2A, KCNT1, and KCNQ2 and with Angelman syndrome (AS). RESULTS: The cohort comprised 510 individuals with a genetic DEE, in whom we observed CSE in 47% and NCSE in 19%. The highest proportion of CSE occurred in patients with SCN1A-associated DEEs, including 181/203 (89%; 95% CI 84-93) patients with Dravet syndrome and 8/15 (53%; 95% CI 27-79) non-Dravet SCN1A-DEEs. CSE was also notable in patients with pathogenic variants in KCNT1 (6/10; 60%; 95% CI 26-88) and SCN2A (8/15; 53%; 95% CI 27-79). NCSE was common in patients with non-Dravet SCN1A-DEEs (8/15; 53%; 95% CI 27-79) and was notable in patients with CHD2-DEEs (6/14; 43%; 95% CI 18-71) and AS (6/19; 32%; 95% CI 13-57). There were 42/510 (8%) deaths among the cohort, producing a mortality rate of 6.1 per 1,000 person-years (95% CI 4.4-8.3). Cases of SUDEP accounted for 19/42 (48%) deaths. Four genes were associated with SUDEP: SCN1A, SCN2A, SCN8A, and STXBP1. The estimated SUDEP rate was 2.8 per 1,000 person-years (95% CI 1.6-4.3). DISCUSSION: We showed that proportions of patients with CSE, NCSE, and SUDEP differ for commonly encountered genetic DEEs. The estimates for each genetic DEE studied will inform early diagnosis and management of status epilepticus and SUDEP and inform disease-specific counseling for patients and families in this high-risk group of conditions.
引用
- Donnan AM, Schneider AL, Russ-Hall S, et al. Rates of Status Epilepticus and Sudden Unexplained Death in Epilepsy in People With Genetic Developmental and Epileptic Encephalopathies. Neurology. 2023. PMID: 36750385. doi:10.1212/WNL.0000000000207080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。